Studies of WP2 will focus on the phenotype of glycaemic deterioration – whether in those individuals at high risk of developing, or in those with recent onset of type 2 diabetes. The objectives are to discover biomarkers that identify those groups of individuals who are likely to have rapid deterioration of glycaemia, and to identify surrogate biomarkers of diabetes progression, to enable targeted therapy by patient stratification. We will utilise the large cohorts available to the consortium to model incident diabetes and diabetes progression in our populations and to complete the phenotyping of these already well-characterised subjects using standard protocols.
WP2 will assimilate data from existing prospective cohorts studies and generate new deep-phenotyping data in studies designed to assess the dynamic process underlying glycaemic deterioration and beta-cell degeneration in individuals at high-risk of developing type 2 diabetes and in those with clinically manifest diabetes. The primary extreme phenotypes that arise from WP2 will be rapid or slow glycaemic deterioration in high risk people with pre-diabetes, and in those with recently diagnosed type 2 diabetes.
Through integration with WP4 and 5, we will identify predictive and surrogate clinical, physiological and genomic biomarkers.
This approach will yield novel biomarkers that will help target current and future medical therapies focused on preventing and treating type 2 diabetes.
- University of Dundee
- University of Bath
- Consiglio Nazionale delle Ricerche
- Helmholtz Zentrum München – Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH
- Imperial College London
- Leiden University Medical Center
- University of Copenhagen
- University of Eastern Finland
- Lunds Universitet
- University of Newcastle upon Tyne
- University of Exeter
- Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patientenzorg
- Novo Nordisk A/S
- Eliy Lilly and Company Ltd
- Laboratories Servier